Page 2 - Aptamer Group News Today

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications in fast moving consumer goods generated as part of its partnership with Unilever.

Aptamer Group PLC on Monday said it filed a patent application aimed at supporting the next stages of commercial advancement with Unilever PLC. The York, England-based biotechnology firm said it...

Aptamer Group announced the submission of a patent application safeguarding newly-crafted Optimer binder sequences on Monday.

Investors' attention on Thursday will be on a raft of economic data releases on the other side of the Atlantic.

All eyes over the coming week will be on the latest inflation data due out in the U.S..

Aptamer Group PLC shares rose on Monday, after it noted progression on its contract with Unilever PLC. Shares in the York, England-based biotechnology firm were up 10% to 0.80 pence each in London on...

Aptamer Group PLC on Tuesday said its new Optimer+ platform delivers improved results compared to standard binders. The York, England-based biotechnology firm said its updated Optimer+ platform can...

Firms seek to develop animal-free binders for lateral flow test to detect disease early

Aptamer Group PLC on Thursday said it has entered the second phase of developing Optimer binders for the early diagnosis of Alzheimers disease alongside Neuro-Bio Ltd. Shares in Aptamer were up 14%...

Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease